Daniel W. Campbell
Known title: DirectorCIK: 0001184200
Associated companies
Transaction History
| NUS | ▲ Buy | Grant | 26,643 | $0 | 6/1/2026 | View on chart |
| NUS | ▼ Sell | Open Market | 9,046 | $110K | 8/29/2025 | View on chart |
| NUS | ▼ Sell | Open Market | 23,391 | $283K | 8/29/2025 | View on chart |
| NUS | ▲ Buy | Grant | 18,008 | $0 | 6/2/2025 | View on chart |
| NUS | ▲ Buy | Grant | 11,330 | $0 | 6/7/2024 | View on chart |
| NUS | ▲ Buy | Grant | 4,232 | $0 | 6/7/2023 | View on chart |
| NUS | ▲ Buy | Grant | 3,179 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nu Skin: Turnaround Narrative Gains Attention
A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.
Nu Skin: Turnaround Narrative Gains Attention. A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.